Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile

Authors: Raphael Lis, Cyril Touboul, Najeeb M Halabi, Abishek Sainath Madduri, Denis Querleu, Jason Mezey, Joel A Malek, Karsten Suhre, Arash Rafii

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

The cross talk between the stroma and cancer cells plays a major role in phenotypic modulation. During peritoneal carcinomatosis ovarian cancer cells interact with mesenchymal stem cells (MSC) resulting in increased metastatic ability. Understanding the transcriptomic changes underlying the phenotypic modulation will allow identification of key genes to target. However in the context of personalized medicine we must consider inter and intra tumoral heterogeneity. In this study we used a pathway-based approach to illustrate the role of cell line background in transcriptomic modification during a cross talk with MSC.

Methods

We used two ovarian cancer cell lines as a surrogate for different ovarian cancer subtypes: OVCAR3 for an epithelial and SKOV3 for a mesenchymal subtype. We co-cultured them with MSCs. Genome wide gene expression was determined after cell sorting. Ingenuity pathway analysis was used to decipher the cell specific transcriptomic changes related to different pro-metastatic traits (Adherence, migration, invasion, proliferation and chemoresistance).

Results

We demonstrate that co-culture of ovarian cancer cells in direct cellular contact with MSCs induces broad transcriptomic changes related to enhance metastatic ability. Genes related to cellular adhesion, invasion, migration, proliferation and chemoresistance were enriched under these experimental conditions. Network analysis of differentially expressed genes clearly shows a cell type specific pattern.

Conclusion

The contact with the mesenchymal niche increase metastatic initiation and expansion through cancer cells’ transcriptome modification dependent of the cellular subtype. Personalized medicine strategy might benefit from network analysis revealing the subtype specific nodes to target to disrupt acquired pro-metastatic profile.
Appendix
Available only for authorised users
Literature
1.
2.
Ceelen WP, Bracke ME: Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol. 2009, 10: 72-79. 10.1016/S1470-2045(08)70335-8.CrossRefPubMed
3.
Zhang S, Wang J, Bilen M, Lin S-H, Stupp S, Satcher R: Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis. 2009, 26: 993-1004. 10.1007/s10585-009-9289-0.CrossRefPubMed
4.
Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS: Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71: 614-624. 10.1158/0008-5472.CAN-10-0538.PubMedCentralCrossRefPubMed
5.
Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, Maleki M, Abdalla SA, Raynaud CM, Querleu D, Al-Azwani E, Malek J, Mirshahi M, Rafii A: Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer. 2011, 128: 715-725. 10.1002/ijc.25619.CrossRefPubMed
6.
Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, zu Bentrup KH, Danka ES, Henkle SL, Scandurro AB: The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci. 2009, 106: 3806-3811. 10.1073/pnas.0900244106.PubMedCentralCrossRefPubMed
7.
Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M, Couderc B: Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer. 2010, 126: 2090-2101.PubMed
8.
Martinet L, Poupot R, Mirshahi P, Rafii A, FourniÈ J-J, Mirshahi M, Poupot M: Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer. 2010, 126: 2143-2152.PubMed
9.
Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE. 2009, 4: e4992-10.1371/journal.pone.0004992.PubMedCentralCrossRefPubMed
10.
Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, Mery E, Mirshahi M, Rafii A: Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med. 2013, 11: 28-10.1186/1479-5876-11-28.PubMedCentralCrossRefPubMed
11.
Cancer Genome Atlas Research N: Integrated genomic analyses of ovarian carcinoma. Nature. 2011, 474: 609-615. 10.1038/nature10166.CrossRef
12.
Malek JA, Martinez A, Mery E, Ferron G, Huang R, Raynaud C, Jouve E, Thiery JP, Querleu D, Rafii A: Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. J Transl Med. 2012, 10: 121-10.1186/1479-5876-10-121.PubMedCentralCrossRefPubMed
13.
Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D, Rafii A: Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One. 2011, 6: e28561-10.1371/journal.pone.0028561.PubMedCentralCrossRefPubMed
14.
Lis R, Touboul C, Raynaud CM, Malek JA, Suhre K, Mirshahi M, Rafii A: Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PLoS One. 2012, 7: e38340-10.1371/journal.pone.0038340.PubMedCentralCrossRefPubMed
15.
Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh D-S, Yoon M-S, Chang CL, Jung JS, Kim JH: Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells. 2008, 26: 789-797. 10.1634/stemcells.2007-0742.CrossRefPubMed
16.
Ahmed N, Riley C, Rice G, Quinn M: Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005, 22: 391-402. 10.1007/s10585-005-1262-y.CrossRefPubMed
17.
Zand L, Feng Q, Roskelley C, Leung P, Auersperg N: Differential effects of cellular fibronectin and plasma fibronectin on ovarian cancer cell adhesion, migration, and invasion. In Vitro Cell Dev Biol - Animal. 2003, 39: 178-182. 10.1007/s11626-003-0013-0.CrossRef
18.
Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, Hedin L: E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997, 74: 275-280. 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.0.CO;2-W.CrossRefPubMed
19.
Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A: Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS ONE. 2011, 6: e16186-10.1371/journal.pone.0016186.PubMedCentralCrossRefPubMed
20.
Kenny HA, Kaur S, Coussens LM, Lengyel E: The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008, 118: 1367-1379. 10.1172/JCI33775.PubMedCentralCrossRefPubMed
21.
Barbieri F, Bajetto A, Florio T: Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol. 2010, 2010: 426956-PubMedCentralCrossRefPubMed
22.
Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011, 475: 222-225. 10.1038/nature10138.PubMedCentralCrossRefPubMed
23.
Chang W, Ma L, Lin L, Gu L, Liu X, Cai H, Yu Y, Tan X, Zhai Y, Xu X, Zhang M, Wu L, Zhang H, Hou J, Wang H, Cao G: Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer. 2009, 125: 2844-2853. 10.1002/ijc.24699.CrossRefPubMed
24.
Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C, Berg D, Penary M, Teissie J, Favre G: In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Ther. 2008, 15: 456-464. 10.1038/cgt.2008.12.CrossRefPubMed
25.
Ramachandran S, Shida D, Nagahashi M, Fang X, Milstien S, Takabe K, Spiegel S: Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. FEBS Lett. 2010, 584: 4077-4082. 10.1016/j.febslet.2010.08.035.PubMedCentralCrossRefPubMed
26.
Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A: The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010, 463: 318-325. 10.1038/nature08712.PubMedCentralCrossRefPubMed
27.
Sher I, Adham SA, Petrik J, Coomber BL: Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer. 2009, 124: 553-561. 10.1002/ijc.23963.CrossRefPubMed
28.
29.
Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008, 11: 231-246. 10.1016/j.drup.2008.08.005.CrossRefPubMed
30.
Miyoshi K, Sato N, Ohuchida K, Mizumoto K, Tanaka M: SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res. 2010, 30: 867-871.PubMed
31.
Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S: SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene. 2011, 30 (49): 4887-4900. 10.1038/onc.2011.198.CrossRefPubMed
32.
Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D, Schwarz MA: Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther. 2010, 9: 632-639. 10.4161/cbt.9.8.11265.CrossRefPubMed
33.
Roman J, Ritzenthaler JD, Roser-Page S, Sun X, Han S: {alpha}5{beta}1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol. 2010, 43: 684-691. 10.1165/rcmb.2009-0375OC.PubMedCentralCrossRefPubMed
34.
De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G: Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature. 2001, 414: 308-313. 10.1038/35104560.CrossRefPubMed
35.
Gupta M, Gupta SK, Balliet AG, Hollander MC, Fornace AJ, Hoffman B, Liebermann DA: Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis. Oncogene. 2005, 24: 7170-7179. 10.1038/sj.onc.1208847.CrossRefPubMed
36.
Dong L, Wen J, Pier E, Zhang X, Zhang B, Dong F, Ziegler N, Mysz M, Armenta R, Cui R: Melanocyte-stimulating hormone directly enhances UV-induced DNA repair in keratinocytes by a xeroderma pigmentosum group a-dependent mechanism. Cancer Res. 2010, 70: 3547-3556. 10.1158/0008-5472.CAN-09-4596.PubMedCentralCrossRefPubMed
37.
De Toni-Costes F, Despeaux M, Bertrand J, Bourogaa E, Ysebaert LØ, Payrastre B, Racaud-Sultan C: A New alpha5beta1 integrin-dependent survival pathway through GSK3Œ ≤ activation in leukemic cells. PLoS ONE. 2010, 5: e9807-10.1371/journal.pone.0009807.PubMedCentralCrossRefPubMed
38.
Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, Ma D: Activation of fibronectin/PI-3 K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008, 261: 108-119. 10.1016/j.canlet.2007.11.022.CrossRefPubMed
39.
Xing H, Cao Y, Weng D, Tao W, Song X, Wang W, Meng L, Xu G, Zhou J, Wang S, Ma D: Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis. 2008, 13: 213-223. 10.1007/s10495-007-0158-5.CrossRefPubMed
40.
Choi J-H, Park JT, Davidson B, Morin PJ, Shih I-M, Wang T-L: Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008, 68: 5716-5723. 10.1158/0008-5472.CAN-08-0001.PubMedCentralCrossRefPubMed
41.
McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ: Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 2011, 121: 3206-3219. 10.1172/JCI45273.PubMedCentralCrossRefPubMed
Metadata
Title
Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile
Authors
Raphael Lis
Cyril Touboul
Najeeb M Halabi
Abishek Sainath Madduri
Denis Querleu
Jason Mezey
Joel A Malek
Karsten Suhre
Arash Rafii
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-59

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue

Research

Delayed treatment with oleanolic acid attenuates tubulointerstitial fibrosis in chronic cyclosporine nephropathy through Nrf2/HO-1 signaling

Research

Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma

Research

Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP)

Research

Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer

Research

Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling

Research

Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits